# Neuralink — Healthcare Investment Intelligence

> medical_device · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) to restore sensory and motor function for patients with paralysis, spinal cord injury, and ALS[1][2]. The company received FDA approval in May 2023 and has completed its first human implant, with plans to scale to 25,000+ channels per implant by 2028[2][3].

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-15. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.